信息详情

Licence variation: spironolactone for acne in women market engagement

2025-02-26

中文

英语 (English)

所属地区: --

所属机构: --

抱歉,该信息暂无中文翻译信息,为您显示项目原文信息。

Published date: 26 February 2025

Open early engagement - This means that a procurement idea is currently active, it is in the early stage of development and judging interest from potential suppliers.

Watch this notice Print this notice
Closing date: 14 March 2025

Contract summary

Industry

  • Project management consultancy services - 72224000

  • Health services - 85100000

  • Location of contract

    England

    Procurement reference

    CF-2900000D0O000000rwimUAA

    Published date

    26 February 2025

    Closing date

    14 March 2025

    Contract type

    Service contract

    Contract is suitable for SMEs?

    Yes

    Contract is suitable for VCSEs?

    No


    Description

    NHS England has published this Preliminary Market Engagement Notice. It is anticipated that there will be two separate contracts to deliver this, as outlined below.
    • Contract A: Prepare an application for a major (type II) MHRA Marketing Authorisation variation for spironolactone.
    • Contract B: Submit the pre-prepared application to the MHRA. Only current Marketing Authorisation Holders of spironolactone are eligible to bid for contract B.

    The licence variation is to add a new indication to the current licence (marketing authorisation) for spironolactone, for treating acne in women.

    For contract A, the Successful Supplier would need to prepare a dossier for the MHRA including:
    • A Risk Management Plan
    • Clinical Overview
    • Revised Summary of Product Characteristics and Patient Information Leaflet
    • Responses to the MHRA's Request(s) for Further Information.

    For contract B, the Successful Supplier would need to:
    • Review the draft regulatory modules and supporting documents prepared by contractor A and either confirm they are complete, or request revisions.
    • Use the final regulatory modules and supporting documents to apply for a major type II licence variation from the MHRA.
    • If granted, update the Summary of Product Characteristics and Patient Information Leaflet with the new indication and related data.

    NHS England would like to gather soft intelligence from the market and is publishing a Request for Information for the two contracts. NHS England would also be pleased to offer 1:1 meetings with potential Suppliers to discuss this innovative partnership approach.
    The Request for Information and further documentation will be available from 26 February 2025 and the deadline for responses will be 14 March 2025 at 12 noon and 1:1 meetings will be 12 noon on 11 March 2025.

    To register an interest in responding to this market engagement exercise and obtain a copy of the Request for Information documentation please go to: http://health.atamis.co.uk. All communications and Request for Information submissions will be conducted via Atamis. The portal can be accessed at any time of the day and it is free to register.
    This notice signals the intention to conduct an information gathering exercise only. This notice does not constitute a call for competition in its own right. Publication of this notice and/ or any responses to it does not commit NHS England and/or respondents to undertaking or participating in any future procurement process, nor does it provide any process exemptions or preferential treatment to any parties expressing an interest. NHS England will not be liable for costs incurrent by any interested party in participating in the information exercise howsoever arising.


    How to apply

    Follow the instructions given in the description or the more information section.


    About the buyer

    Contact name

    Leigh Parker

    Address

    7-8 Wellington Street
    Leeds
    LS1 4AP
    GB

    Email

    leigh.parker1@nhs.net


    Share this notice

    Is there anything wrong with this page?

    温馨提示:

    本网站为您提供准确和及时的招投标信息,但招投标信息存在着变更的可能,请您务必在交易前向招标代理机构或招标人咨询投标详细要求,有关招标的具体要求及情况以招标代理机构或招标人的解释为准。
           如果您对这篇招标信息有任何补充或修改建议,请告知我们。

    猜你喜欢

    首页 > 英国 > Licence variation: spironolactone for acne in women market engagement